Allergy Immunotherapy denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for allergy immunotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Allergy Immunotherapy as "Not FDA-Approved" — and Why You Can Appeal

This denial almost always targets a specific delivery format rather than immunotherapy as a whole. Subcutaneous allergen immunotherapy (allergy shots) uses compounded, patient-specific allergen extracts — these extracts are regulated by the FDA under a separate biologics framework and are lawfully produced under that framework, but individual compounded mixes are not individually "FDA-approved" in the same way a brand-name drug is. Sublingual drops (SLIT drops) are similarly compounded and lack individual FDA approval, whereas certain sublingual tablets for specific allergens do carry FDA approval. Humana's "not FDA-approved" denial frequently applies to SLIT drops or to off-label allergen combinations.

The key distinction to establish in your appeal is whether Humana's own published clinical policy actually requires FDA approval for the specific product type, or whether it accepts compounded extracts under the established regulatory framework for allergen biologics.

## Federal Appeal Rights

• ACA Section 2719 external review: independent reviewers apply clinical and regulatory standards, not just Humana's internal policy — and the FDA's regulatory framework for allergen extracts is well-established.
• ERISA Section 503 entitles you to the full written basis for the "not FDA-approved" determination, including the policy provision and the regulatory standard Humana applied.
• The external review window is approximately four months from the denial notice for most plans.
• Expedited review is available for time-sensitive clinical situations.

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter; identify precisely which product Humana claims lacks FDA approval. 2. Ask your allergist whether the product is (a) a compounded extract produced under the FDA's allergen extract biologics framework, or (b) an off-label sublingual formulation. 3. File a Level 1 internal appeal with a letter from your allergist explaining the regulatory status of the specific product and Humana's own policy language on this point. 4. If upheld, file for external review — independent reviewers frequently recognize the established regulatory framework for allergen extracts.

## Documentation to Gather

• Prescribing allergist's letter addressing regulatory status of the specific product and explaining how it falls within the established FDA regulatory framework for allergen extracts (or, for sublingual tablets, providing the FDA approval reference)
• Humana's published clinical policy for allergy immunotherapy — specifically the language regarding FDA approval requirements — to confirm whether Humana's own policy actually imposes an approval requirement for this product type
• Applicable specialty society guidance (e.g., AAAAI or ACAAI position statements) on the specific delivery route
• Patient chart documentation confirming the clinical indication and prior treatment history

## Criteria-Mapping Structure

| Humana Criterion (from policy) | Supporting Documentation | |---|---| | Regulatory status of the specific product | Allergist letter + FDA framework reference | | Clinical indication match | Diagnosis + allergy testing records | | Specialty society endorsement of this route | AAAAI / ACAAI guideline reference |

Your appeal should challenge Humana to identify the exact policy provision requiring individual FDA approval for this product type and explain how that requirement applies to allergen extracts regulated under the biologics framework. This framing frequently reveals that Humana's internal coding, rather than their published policy, generated the denial.